Canakinumab prophylaxis resolves active gout flares within 48 hours and prevents new gout flares among patients initiating pegloticase + methotrexate, according to a study presented at the 2024 European Alliance of Associations for Rheumatology (EULAR) in Vienna, Austria.

The US Food and Drug Administration (FDA) approved pegloticase + methotrexate in July 2022. Although the pivotal trial MIRROR supported the safety and efficacy of pegloticase + methotrexate with a response rate of 71% at month 6 (placebo: 39%), gout flares were the most common adverse event. More than half (54%) of the participants experienced gout flares, despite being on daily non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine prophylaxis and pre-infusion IV methylprednisone 125 mg to tame gout flares.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/canakinumab-prophylaxis-resolves-active-gout-flares-within-48-hours